1. 康哲药业
  2. 康哲药业
  3. 康哲药业

Business

Industry Overview

The global pharmaceutical industry kept growing recently, which was benefiting from increased consciousness of human health, marked trend of aging population, as well as the innovation and development of pharmaceutical technology. Accordingly, the market of prescription drugs has been keeping growing strongly due to the considerable medical demand produced by more than 1.3 billion population of Chinese market. According to industry reports, the Chinese pharmaceutical market was growing at a compound annual growth rate (CAGR) of 11.4% from 2012 to 2016 of which the prescription drug market was growing at a CAGR of 11.6%. The sales of imported prescription drugs in Chinese market reached RMB96.3 billion in 2016, increasing at 13.1% CAGR from 2012 to 2016, which outperformed the growth rate of overall sales market of prescription drugs in China.

More>>

Core Business

CMS focuses on the two core aspects of the China’s prescription drug industry chain – innovative product R&D and professional academic promotion. The Group has established a rigorous new product evaluation system and a diversified new product portfolio plan. The products promoted by the Group all have the characteristics of high quality standards, exact curative effect, and competitive advantages different from similar products. Therefore, our products have a good historical sales record under the re-positioning, planning and professional academic promotion. At present, the Group mainly distributes and sells 20 drug products, the therapeutic field of which has basically covered the main clinical departments of top tertiary hospitals in China.

More>>

Innovative Research

The Group is fully aware that pharmaceutical companies are empowered by innovative research and development. It has determined the innovative research and development as its core strategic path and the combination of collaborative R&D and in-house R&D as the method to accelerate the pace of innovative research and development. So far the Group has participated in the equity investment of a number of R&D companies in the United Kingdom, France, the United States, Switzerland, etc. and has possessed innovative platform focused on neurological wellness, central nervous system, new approach to the treatment of infectious disease, nanomedicine therapy, acute thrombotic disease therapy, oral T-cell immunotherapy and the R&D of medicines for oncology and immunotherapy; at the same time, the Group has the assets and market rights of more than ten main innovative patented products under research in China and some Asia-Pacific countries. We will develop clinical trials and marketing plans in China based on the characteristics of each innovative patented products to bring more effective disease treatment drugs to Chinese doctors and patients.

More>>

Investor Relations

Announcements & Circulars

  • 2019-04-11
    Voluntary and Business Update Announcement Helius Announces Update on FDA's Review of its Request for De Novo Classification and 510(k) Clearance of the PoNS Device
  • 2019-04-04
    Extension of the Exclusive Promotion Right of XinHuoSu and Imdur to 31 December 2021
  • 2019-04-03
    NOTIFICATION LETTER
  • 2019-04-01
    Monthly Return of Equity Issuer on Movements in Securities
  • 2019-03-22
    NOTIFICATION LETTER
  • 2019-03-22
    FORM OF PROXY
  • More>>

    Financial Reports

  • Annual Report 2018

  • Interim Report 2018

  • Annual Report 2017

  • Interim Report 2017

  • Annual Report 2016

  • Interim Report 2016

  • More>>

    Stock Quotes